Atopic Dermatitis is the most common chronic inflammatory skin disease and has a profound effect on the quality of life of patients. After almost 50 years without major breakthroughs in the treatment of Atopic Dermatitis, there are finally new drugs becoming available that will hopefully fill the large unmet needs in the treatment of Atopic Dermatitis.
A major issue that we are facing is the heterogeneity of the disease. Although it is well known that Atopic Dermatitis is highly heterogeneous and many attempts have been made to define clinical phenotypes, science so far has not succeeded in establishing generally accepted definitions of clinical phenotypes.
Our mission is to develop novel ways to better characterize Atopic Dermatitis patients by integrating clinical, serological, cellular and molecular biomarkers. This will lead to a better understanding of disease mechanisms and contribute to precision medicine. Additionally, we aim to improve the self-management of atopic dermatitis, including the use of eHealth interventions.
- Biomarkers in atopic dermatitis
- Improving systemic and biological treatment of atopic dermatitis
- Self-management and eHealth
More information on specific research internships can be found on the UMC Utrecht website.